Factors in Selecting First-Line Therapy for PD-L1–High Metastatic NSCLC

Video

Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer.

Case: A 72-Year-Old With Advanced NSCLC Cancer

Initial presentation

  • KD is a 72 y/o female who presents to her primary care physician complaining of fatigue and a persistent cough.
    • PMH:
      • Hyperlipidemia (controlled)
      • Anxiety (controlled)
      • COPD (controlled)
    • SMH: quit smoking 3 years ago and enjoys social drinking with her family
    • FH: she lives alone but her kids and grandkids live nearby

Clinical workup

  • Current Labs:
    • CBC panel: Normal
    • Liver function/Renal function: Normal
  • PD-L1: 85%
  • ECOG 1
  • Molecular testing: (-) EGFR, ALK, ROS1
  • CT scan of the head and neck showed a 5cm nodule in the right upper lobe of lung
    • CT guided biopsy of the upper lobe confirms non-squamous cell carcinoma
  • Abdominal CT scan shows liver metastases
  • Diagnosis consistent with Stage IV non-small cell lung adenocarcinoma

Transcript:

Marina Chiara Garassino, MD: This patient has a PD-L1 of 85%. She is a former smoker who quit 3 years ago, so she’s considered in the family of smoker patients. She’s without actionable mutations. From the results we have, the single-agent approach is perfect for this patient. However, 1 point that’s important in this patient is that has a lot of liver lesions, so to lower the risk, chemotherapy and immunotherapy can be considered.

The results from the data that we’re presenting at the ESMO [European Society for Medical Oncology] Virtual Plenary came from the Flatiron database. They showed that the single agent is always the same as the combination of chemotherapy and immunotherapy. There’s 1 exception: patients who have never smoked. For patients who have never smoked, I consider the combination with chemotherapy.

There’s also a meta-analysis that was presented by the FDA at ASCO [American Society of Clinical Oncology Annual Meeting] last year that showed that chemotherapy-immunotherapy is slightly superior to the single agent alone. But they weren’t able to identify the patients who could benefit from the chemotherapy-immunotherapy. In my practice, I treat the patient with a single agent if they have a PD-L1 that’s very high—like 85%, in this case—with 1 of the drugs that are FDA approved: pembrolizumab [Keytruda], atezolizumab [Tecentriq], or cemiplimab [Libtayo]. Any 1 is the same as the other. I consider to add to the chemotherapy only if there’s a risk of losing the patient because the burden of the tumor is too high or if the patients are never smokers.

Forty-five percent of patients are PD-L1. That’s not an absolute number because you have to count the cells that are PD-L1–positive among 100 cells. The majority of patients have a PD-L1 of more than 50%, and the majority are PD-L1 0. It’s rare to find 45%. In general, I discuss these cases with the patients. They’re between 1% and 49%. They are patients for whom the best treatment is potentially chemotherapy and immunotherapy. Clearly, they’re close to 50%, so we can also discuss monotherapy. It’s important to remember that most of the benefit for patients with more than 50% is in those patients who have 85%, like in this case, or a very high PD-L1. If it’s 45%, maybe I would treat them with a combination with chemotherapy.

Transcript edited for clarity.

Related Videos
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Related Content